Explore PFE stock price, latest earnings, analyst ratings, technical analysis, and forecast. Is PFE stock a buy? Get balanced insights for investors as of March 2026.
Introduction
Pfizer develops medicines and vaccines. It treats diseases like cancer and heart issues. Investors watch PFE stock now due to post-COVID shifts and new drugs. Healthcare stocks face patent cliffs amid steady market conditions.
PFE stock draws focus for its dividend yield. Broader pharma sector deals with pricing pressures. Economic stability aids drug demand.
Latest Stock Price & Trend
PFE stock closed at $27.52 on the last market day. This gives a market cap of $157.1 billion.
One-day performance showed fluctuation between $27.00 and $27.67. It ended up slightly from the low.
Over five days, it rose 1.19% from recent lows around $24.95. The one-month trend gained 0.59%. Three months up 0.95%, but six months down 0.31%. Year-to-date, PFE stock advanced 2.33%.
The 52-week low hit $20.92, high $27.94. Overall trend stays sideways to mildly bullish. Investors see stability, not big rallies. It hints at steady value amid volatility.
Technical Analysis
Support levels sit near $22.81, where price often rebounds. Resistance at $27.73 blocks upsides. These matter as they signal buy or sell zones for traders.
RSI at 63.9 shows neutral, not overbought or oversold. Values above 70 warn of pullbacks; below 30 signal buys.
MACD line below signal hints bearish momentum short-term. Yet overall indicators lean bullish.
The 50-day moving average at $26.4 tops the 200-day at $24.9. No death cross; this supports uptrend. Volume hit 41.88 million shares lately, average levels.
Analyst Ratings & Price Targets
Of 28 analysts, consensus aims at $31.44 average target. High $50 from HSBC; low $25 from RBC Capital. Recent calls include RBC underperform at $25 on Feb 25, 2026.
Barclays and Cantor Fitzgerald rated hold or equal-weight. Sentiment mixes hold with some buys. This suggests caution but upside potential for PFE stock.
Wall Street views reflect pipeline hopes versus COVID drop. Investors use this for conviction checks.
Insider Activity
Insiders net bought over last two years, total $390,000 positive. Jennifer B. Damico sold most at $210,000.
Recent SEC filings show small tax-related sales, like 1,058 shares at $27.09. No big buying bursts.
Trend implies mild confidence. Managers hold steady, not aggressive. Watch for larger moves as signals.
Valuation Analysis
Trailing P/E ratio stands at 20.39. Forward looks lower around 17.92. Price-to-sales not detailed, but revenue base supports.
Q4 2025 revenue $17.6 billion, down 1% YoY operationally 3%. Ex-COVID, up 9%. EPS TTM $1.72, quarterly $0.66 adjusted.
Free cash flow strong from cost cuts. Debt manageable with $25.5 billion non-US revenue. Versus peers like Johnson & Johnson, PFE appears fairly valued. Not cheap, but dividend 6.2% attracts.
Recent Earnings & Catalysts
Q4 2025 revenue $17.6 billion beat some views despite COVID drop. Adjusted EPS $0.66 topped estimates. Full-year 2025 solid; 2026 guidance reaffirmed.
Guidance cites oncology, Abrysvo vaccine growth. Eliquis up sharply. Acquisition of Metsera boosts obesity drugs.
Stock dipped post-earnings on COVID reliance. But non-COVID gains lift outlook.
Bullish Case
Pipeline includes vepdegestrant Phase 3 success. Oncology biosimilars grow fast.
Eliquis, Prevnar demand steady. Cost cuts raise EPS guidance. AI scales operations. Diversified revenue outside China buffers risks.
Bearish Case
COVID sales decline pressures top line. Patent expiries loom to 2041. Competition in obesity from rivals.
Margin squeezes possible. Regulatory hurdles on pricing. Short interest 2.58% shows some doubt.
Market Sentiment
Short interest at 2.58%, days to cover 2.4. Low bets against.
Institutions own 66%, Vanguard tops at 9.4%. Steady holding. Options data limited, but bullish puts noted.
Sentiment neutral to optimistic on pipeline. Retail favors value play.
Short-Term Outlook
Technicals show support hold. Volume steady, RSI neutral. Momentum sideways next weeks. Watch resistance break.
Medium to Long-Term Outlook
Strong R&D in oncology, vaccines. Financial health solid with cash flow. Competitive in key areas. Hold for dividend; accumulate on dips for growth. Risks from competition persist.
FAQ
Is PFE stock a buy right now? Depends on risk tolerance. Fair value with yield suits income seekers.
What is the price target for PFE stock? Average $31.44, range $25-$50.
PFE earnings next? Q1 2026 due soon; watch non-COVID growth.
What are major risks for PFE stock? COVID decline, competition, patents.
PFE forecast long-term? Positive on pipeline if execution holds.
Suggestions
Compare with [Opendoor stock analysis].
See our [MRK stock forecast].
Read [pharma sector valuation].
Final Balanced Conclusion
Hold PFE stock. Solid dividend and pipeline balance COVID headwinds. Watch earnings for shifts.
Disclaimer: This article is for informational purposes only and not financial advice.